Senior Independent Director
Appointed: March 15, 2010
Committee membership: Remuneration Committee, Nomination & Governance Committee and Science & Technology Committee
William "Bill" served as Non-Executive Director prior to his appointment as Senior Independent Non-Executive Director on 28 April, 2016. Bill will retire from the Board with effect from the conclusion of the 2018 Annual General Meeting.
Skills & experience: Bill brings to the Board extensive international R&D, commercial, business development and operational experience in the pharmaceutical sector. He worked for Roche from 1986 until 2009; most recently holding the position of CEO of its pharmaceuticals division and serving as a member of the Roche Group Corporate Executive Committee. Bill is a former Non-Executive Director of Roche Holding AG and Chugai Pharmaceutical Co, Ltd, and former Chairman of Biotie Therapies Corp. Bill holds a BA (Hons) in Business Economics from the University of Strathclyde.
Key appointments: Mesoblast Limited (Vice Chairman), Vestergaard Frandsen (Vice Chairman), Molecular Partners (Vice Chairman and Director), Wellcome Trust (Governor and Trustee), Institute of Cancer Research (Trustee) and University of Cologne/Bonn Center for Integrated Oncology (Scientific Advisory Board Member).